This websites contains videos from YouTube. This company uses
cookies (third party cookies). If you do not want them to use these
cookies, you can indicate so here. However, this does mean that you
will not be able to watch videos on this website. We also make use
of our own cookies in order to improve our website. We don't share
our data with other parties. Which cookies are involved?
user experience. If you do not want to accept these cookies,
indicate so here. Which cookies are involved?
In 2013 I finished my Master in Pharmacy at Utrecht University.
In my master research project I studied the pleiotropic effects of
statins and ACE-inhibitors in patients with COPD at The University
of Alabama at Birmingham, United States. Thereafter, I worked as a
pharmacist in a hospital pharmacy. I work as a Ph.D. student in the
group of Prof. Dr. Jan Schellens. My projects focus on phase I/II
In 2012 I finished medical school at the University of Amsterdam
cum laude. During medical school I did an internship oncology at
the NKI. The first year after graduating I worked as a resident of
internal medicine in Flevo Hospital. Hereafter I entered a resident
training program to become an internist. The past eighteen months I
worked as a resident in internal medicine.
Due to increasing interest in research I decided to interrupt my
residency. Currently I work as a PhD student in the Jan Schellens
group jointly with the group of Sabine Linn. During my PhD studies
I will focus on phase I/II clinical trials. My main focus will
be the REVIVAL study of carboplatin-olaparib in BRCAm breast cancer
I studied medicine at VUmc. In July 2015 I obtained my master's
degree and started working as ANIOS oncology at the SLAZ hospital
for 9 months.
Since this month I started my PhD in the group of prof Schellens.
My project consists of phase I clinical studies with nivolumab in
combination with newer therapies.
As a PhD student in the group of Prof. Jan Schellens the focus
of my research is on the safety, feasibility and cost-effectiveness
of genotype- and phenotype-directed individualized dosing of
fluoropyrimidines. In August 2014 I finished my master in Pharmacy
at the Utrecht University cum laude. During my master I did an
internship at the University of California in San Francisco where I
studied the Ras pathway in colorectal cancer.
I finished medical school at the University of Amsterdam in
january 2014. Hereafter I worked for 1 year as a resident in
internal medicine at the AvL/NKI and for 8 months in Spaarne
hospital. Due to my work in the clinic I became more and more
interested in research, especially in oncology. Now I work as
a PhD student in the group of prof Schellens. I focus on
phase I studies related to targeted therapy for BRAF mutated
I am involved as an independent researcher in the development
and validation of non-invasive predictive and pharmacodynamic
biomarker assays for monitoring the effect of molecular targeted
anticancer agents. These assays can be used to predict if a patient
will benefit from a particular treatment. This work includes: 1.
enzymatic activity assays for dihydropyrimidine dehydrogenase,
thymidine synthase, and polyADPribose polymerase. 2. assays for the
enumeration of circulating epithelial and melanoma tumor cells.
My name is Willeke Ros and I am a PhD student at Jan Schellens
group. I have completed my bachelor in Biology and my master in
Biomedical Sciences at Leiden University. During my studies I have
performed various internships focusing mostly on fundamental
research questions. However, during my last internship at the
University of Wisconsin-Madison, I did research which was part of
clinical trials. I enjoyed the translational nature of the research
and decided I wanted to continue doing clinical research. During my
PhD studies I will focus on phase I/II clinical trials related to
I finished my master in Pharmacy in April 2018 and shortly
after started my PhD at the NKI-AVL. The main focus of my PhD will
be improving the safety, feasibility and cost-effectiveness of
genotype- and phenotype-directed individualized dosing of
Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data
(2015) Lancet Oncol. Oct 21. pii: S1470-2045(15)00286-7. doi: 10.1016/S1470-2045(15)00286-7. [Epub ahead of print]
Meulendijks D, Henricks LM, Sonke GS, Deenen MJ, Froehlich TK, Amstutz U, Largiadèr CR, Jennings BA, Marinaki AM, Sanderson JD, Kleibl et al.